Drug use for gastrointestinal symptoms during pregnancy: A French nationwide study 2010-2018.

Citation metadata

From: PLoS ONE(Vol. 16, Issue 1)
Publisher: Public Library of Science
Document Type: Report
Length: 5,051 words
Lexile Measure: 1370L

Document controls

Main content

Abstract :

Purpose To describe drug prescription for gastrointestinal symptoms during pregnancy. Methods Using the French national health database, we identified pregnancies ending with a birth between April 2010 and December 2018, in France. We studied prescription of antacids, antispasmodics, antinauseants, laxatives and antidiarrheals during pregnancy, between two trimesters before and two trimesters after delivery. We also assessed hospitalization for gastrointestinal symptoms during pregnancy. Results Among 6,365,471 pregnancies, 4,452,779 (74.0%) received at least one gastrointestinal drug during pregnancy; 2,228,275 (37.0%) received an antacid, 3,096,858 (51.5%) an antispasmodic, 1,861,731 (31.0%) an antinauseant, 919,116 (15.3%) a laxative and 617,808 (10.3%) an antidiarrheal. Prescription of proton pump inhibitors doubled from 12.2% in 2010 to 26.0% in 2018, while domperidone use decreased from 18.3% in 2010 to 2.2% in 2018. In addition, prescription of antacids increased from 7.0% during the trimester before pregnancy to 11.8% during the 1.sup.st trimester, 17.0% during the 2.sup.nd trimester and 23.4% during the 3.sup.rd trimester. Antispasmodic use was 10.6% during the trimester before pregnancy, 23.1% during the 1.sup.st trimester, 25.2% during the 2.sup.nd trimester and 24.0% during the 3.sup.rd trimester. Prescription of antinauseant drugs increased from 5.0% during the trimester before pregnancy to 25.7% during the 1.sup.st trimester, then decreased to 6.4% during the 2.sup.nd trimester and 3.2% during the 3.sup.rd trimester. Nausea/vomiting was the most common cause of hospitalization for gastrointestinal symptoms or diseases during pregnancy, although it accounted for only 1.0% of pregnancies. Conclusions Approximately three-quarters of women use drugs for gastrointestinal symptoms during pregnancy in France. Prescription of gastrointestinal drugs during pregnancy should be the subject of more detailed risk-benefit assessment and recommendations.

Source Citation

Source Citation   

Gale Document Number: GALE|A649336045